Galectin Therapeutics Inc.

NASDAQ:GALT

Biotechnology

Healthcare
$2.98 +1.62%

+$0.05 today

Market cap
$196.25M
Beta
0.49
P/E (TTM)
-7.1
EPS (TTM)
-$0.40
52W Low $1.85High $7.13

Volume 0.23M

Average 0.32M

GALT Interest Income

Income earned on cash, deposits, and investments held by the company.

Galectin Therapeutics Inc.NASDAQ: GALT

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income growth accelerates

Q1 FY2026 interest income of $36K rose 2.9% year over year, ahead of the -56.5% change in trailing-twelve-month interest income. Sequentially, it rose 38.5% from the prior quarter. Over 3 fiscal years it compounded at +34.3% a year.

Context

  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.9% holds above the trailing-twelve-month pace of -56.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$36K+38.5% QoQ
Last fiscal yearDec 2025
$126K-62.7% YoY
LTMMar 2026
$127K-56.5% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.9%——
1 year-62.7%——
3-year CAGR+34.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
126K USD
Year-over-year change
-62.7%
4-year CAGR
+154.6%

Interest Income vs competitors

How GALT compares with its peers on the latest reported figures

  • GALT's LTM Mar 2026 interest income of $127K is the 9th highest of the 10 companies compared; the peer median is $6.23M.
  • Its year-over-year change of -56.5% is the 5th highest of 7, against a peer median of -17.2%.
  • Over three fiscal years its annual growth of +34.3% compares with a peer median of +46.2%.
GALT Competitors Peer median
Interest Income for GALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$12.81M -9.0%+39.8%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$9.04M +57.4%——
ALTAltimmune, Inc.LTM Mar 2026$8.9M +23.5%+38.0%24713.9%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$6.36M —+277.3%—
AURAAura Biosciences, Inc.LTM Mar 2026$6.23M -25.3%+52.7%—
ENGNenGene Holdings Inc.LTM Apr 2026$4.29M -63.1%+318.1%—
QSIQuantum-Si incorporatedLTM Mar 2026$1.74M ——94.2%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$944K -79.3%+28.9%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$127K -56.5%+34.3%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding GALT) $6.23M-17.2%+46.2%12404.0%

Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development23.82M31.74M32.13M36.57M14.29M
Selling, General & Admin6.36M6.62M5.94M5.86M5.8M
Operating Expenses30.18M38.35M38.07M42.43M20.09M
Depreciation & Amortization41K32K33K37K53K
EBITDA(30M)(37.71M)(38.24M)(41.47M)(23.45M)
EBITDA Margin—————
Operating Income(30.18M)(38.35M)(38.07M)(42.43M)(20.09M)
Operating Margin—————
Interest Income3K52K230K338K126K
Interest Expense489K1.03M2.79M5.54M7.33M
Other Income / Expenses(348K)(424K)(2.99M)(4.61M)(10.75M)
Income Before Tax(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Net Margin—————
EPS (Basic)(0.52)(0.65)(0.74)(0.76)(0.48)
EPS (Diluted)(0.52)(0.65)(0.74)(0.76)(0.48)
Weighted Avg Shares58.53M59.39M60.16M62.31M63.9M
Weighted Avg Shares (Diluted)58.53M59.39M60.16M62.31M63.9M

Galectin Therapeutics Inc.

NASDAQ:GALT

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.